Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT – RECIST 1.1 vs. PERCIST 1.0

Odawara, Soichi; Kitajima, Kazuhiro; Katsuura, Takayuki; Kurahashi, Yasunori; Shinohara, Hisashi; Yamakado, Koichiro

doi:10.1016/j.ejrad.2018.02.009

Cited by 30 publications

(47 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The appropriate review board at each institution approved the study and waived the requirement for patient informed consent. The clinical database of each institution was searched for consecutive patients with newly diagnosed oesophageal cancer who underwent baseline and follow-up 18 F-FDG-PET/CT examinations before and after NACRT, respectively, prior to planned surgical resection, and thereafter, underwent surgery between January 2007 and June 2016. The search yielded 83 patients, and primary oesophageal cancer was confirmed by endoscopic biopsy.…”

Section: Patientsmentioning

confidence: 99%

“…Each patient was examined using the same PET/CT system for baseline and follow-up 18 F-FDG-PET/CT examinations. The mean (AEstandard deviation [SD]) interval between baseline 18 F-FDG-PET/CT examination and initiation of NACRT was 20AE10 days (range 1e50 days).…”

Section: Patientsmentioning

confidence: 99%

“…The mean (AEstandard deviation [SD]) interval between baseline 18 F-FDG-PET/CT examination and initiation of NACRT was 20AE10 days (range 1e50 days). The mean (AESD) interval between completion of NACRT and follow-up 18 F-FDG-PET/CT examination was 31AE10 days (range 10e63 days), while that between follow-up 18 F-FDG-PET/CT examination and surgery was 25AE15 days (range 1e69 days). Surgical procedures consisted of subtotal oesophagectomy with two-or three-field lymphadenectomy and gastric tube reconstruction.…”

Section: Patientsmentioning

confidence: 99%

“…The concurrent chemotherapy regimen consisted of cisplatin/5-fluorouracil (FP; n¼42, [one cycle, n¼3; two cycles, n¼36 and three cycles, n¼3]), cisplatin/5fluorouracil/docetaxel (DCF; n¼20, [all patents with two cycles]) or FP þ DCF (n¼9, [FP two cycles þ DCF one cycle, n¼5; FP one cycle þ DCF one cycle, n¼2; FP two cycles þ DCF two cycles, n¼1 and FP two cycles þ DCF three cycles, n¼1]). 18…”

Section: Nacrtmentioning

confidence: 99%

“…Observers recorded their confidence level by using a five-score scale, in which 0 ¼ no visible uptake, 1 ¼ weaker-than-normal uptake surrounding organs as muscle, 2 ¼ mild uptake (between 1 and 3), 3 ¼ similar-to-liver uptake, and 4 ¼ higher-than-liver uptake. 17 For determination of the presence or absence of focal 18 F-FDG uptake in the primary lesion, scores 0e1 and 2e4 were non-visible and visible, respectively. In cases of disagreement, consensus was reached by the original two readers and a third radiologist (15 years of experience in PET/CT interpretation).…”

Section: F-fdg-pet/ct Examinationsmentioning

confidence: 99%

See 4 more Smart Citations

The clinical value of PERCIST to predict tumour response and prognosis of patients with oesophageal cancer treated by neoadjuvant chemoradiotherapy

et al. 2020

View full text Add to dashboard Cite

To examine whether Positron Emission Tomography Response Criteria in Solid Tumours (PERCIST) is useful to predict tumour response and prognosis of patients with oesophageal cancer who received neoadjuvant chemoradiotherapy (NACRT) followed by surgery. MATERIALS AND METHODS: This multicentre retrospective study included 60 patients with oesophageal cancer who underwent 2-[ 18 F]-fluoro-2-deoxy-D-glucose positron-emission tomography/computed tomography (18 F-FDG-PET/CT) before and after NACRT prior to surgery from January 2007 and June 2016. The correlation between pathological response and PERCIST was assessed by c 2 test. The prognostic significance was assessed by the KaplaneMeier method and Cox regression analysis. RESULTS: There were 30 responders and 30 non-responders pathologically. The complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), and progressive metabolic disease (PMD) were seen in 22, 29, seven, and two patients, respectively. There was a significant correlation between pathological response and PERCIST (p<0.001). Forty patients showed eventual progression, and 20 patients were alive without progression between the start of NACRT and last clinical follow-up (median follow-up period; 27 months [range, 3e107]). Pathological stage and PERCIST were significant for progressionfree survival (PFS; p¼0.044 and 0.006, respectively) and also significant for overall survival

show abstract

Section: Patientsmentioning

confidence: 99%

Section: Patientsmentioning

confidence: 99%

Section: Patientsmentioning

confidence: 99%

Section: Nacrtmentioning

confidence: 99%

Section: F-fdg-pet/ct Examinationsmentioning

confidence: 99%

See 3 more Smart Citations

The clinical value of PERCIST to predict tumour response and prognosis of patients with oesophageal cancer treated by neoadjuvant chemoradiotherapy

et al. 2020

View full text Add to dashboard Cite

show abstract

Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma

Liu,

Chen,

Zhang

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

PurposeA pathologic complete response (pCR) to neoadjuvant chemoradiotherapy (nCRT) is seen in up to 40% of the patients with esophageal squamous cell carcinoma (ESCC). No nomogram has been constructed for the prediction of pCR for patients whose primary chemotherapy was a taxane‐based regimen. The aim is to identify characteristics associated with a pCR through analyzing multiple pre‐ and post‐nCRT variables and to develop a nomogram for the prediction of pCR for these patients by integrating clinicopathological characteristics and hematological biomarkers.Materials and MethodsWe analyzed 293 patients with ESCC who underwent nCRT followed by esophagectomy. Clinicopathological factors, hematological parameters before nCRT, and hematotoxicity during nCRT were collected. Univariate and multivariate logistic regression analyses were performed to identify predictive factors for pCR. A nomogram model was built and evaluated for both discrimination and calibration.ResultsAfter surgery, 37.88% of the study patients achieved pCR. Six variables were included in the nomogram: sex, cN stage, chemotherapy regimen, duration of nCRT, pre‐nCRT neutrophil‐to‐lymphocyte ratio (NLR), and pre‐nCRT platelet‐to‐lymphocyte ratio (PLR). The nomogram indicated good accuracy and consistency in predicting pCR, with a C‐index of 0.743 (95% confidence interval: 0.686, 0.800) and a p value of 0.600 (>0.05) in the Hosmer–Lemeshow goodness‐of‐fit test.ConclusionsFemale, earlier cN stage, duration of nCRT (< 62 days), chemotherapy regimen of taxane plus platinum, pre‐nCRT NLR (≥2.199), and pre‐nCRT PLR (≥99.302) were significantly associated with a higher pCR in ESCC patients whose primary chemotherapy was a taxane‐based regimen for nCRT. A nomogram was developed and internally validated, showing good accuracy and consistency.

show abstract

Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST – multicenter study in Japan

Kitajima

Nakatani

Yamaguchi

et al. 2018

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT – RECIST 1.1 vs. PERCIST 1.0

Cited by 30 publications

References 12 publications

The clinical value of PERCIST to predict tumour response and prognosis of patients with oesophageal cancer treated by neoadjuvant chemoradiotherapy

The clinical value of PERCIST to predict tumour response and prognosis of patients with oesophageal cancer treated by neoadjuvant chemoradiotherapy

Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma

Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST – multicenter study in Japan

Contact Info

Product

Resources

About